Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07205081 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability and PK of ATTO-3712 in Healthy Volunteers and Patients With Atopic Dermatitis
A Phase 1 study, sponsored by Attovia Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
NCT07205081 is a Phase 1 study that is active but no longer recruiting, run by Attovia Therapeutics. The registered enrollment target is 72 participants.
The verdict
NCT07205081, a Phase 1 study, is active but no longer recruiting, sponsored by Attovia Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to assess the safety, tolerability, and pharmacokinetics of ATTO-3712 in healthy adults and patients with atopic dermatitis. The main questions it aims to answer are: What medical problems do participants have when taking ATTO-3712? How long does ATTO-3712 stay in the body after dosing? Researchers will compare ATTO-3712 to a placebo (a look-alike substance that contains no drug). Participants will be dosed with ATTO-3712 or a placebo, visit the clinic for checkups and tests, and keep a diary of their symptoms.
Interventions
- DRUG Placebo
- DRUG ATTO-3712
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2025-10-22 |
| Est. Completion | 2026-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07205081
The ClinicalTrials.gov registry entry for NCT07205081 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Attovia Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07205081 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07205081 about?
NCT07205081 is a clinical study titled "Safety, Tolerability and PK of ATTO-3712 in Healthy Volunteers and Patients With Atopic Dermatitis". The goal of this clinical trial is to assess the safety, tolerability, and pharmacokinetics of ATTO-3712 in healthy adults and patients with atopic dermatitis. The main questions it aims to answer are: What medical problems do participants have when taking ATTO-3712? How long does ATTO-3712 stay i...
What is the current status of trial NCT07205081?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2025-10-22. Estimated completion is 2026-10.
What interventions are being tested in trial NCT07205081?
The interventions under investigation include: Placebo (DRUG), ATTO-3712 (DRUG).
Who is sponsoring clinical trial NCT07205081?
This trial is sponsored by Attovia Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.